(Q73784645)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRH (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

A Westrin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

R Ekman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

G Regnéll

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

L Träskman-Bendz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 April 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

European Neuropsychopharmacology

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

135-143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

Low levels of somatostatin in human CSF mark depressive episodes

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Elevated CSF CRF in suicide victims

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Cerebrospinal fluid neuropeptides in mood disorder and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Central Nervous System Regulation of Adrenocorticotropin Secretion: Role of Somatostatins*

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of Schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

A 5-year follow-up study of suicide attempts

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

CSF somatostatin in anorexia nervosa and bulimia: relationship to the hypothalamic pituitary-adrenal cortical axis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indices of corticotropin-releasing hormone and cortisol secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Diurnal variation of cerebrospinal fluid immunoreactive corticotropin-releasing hormone levels in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Long-term effects of alprazolam and imipramine on cerebrospinal fluid monoamine metabolites and neuropeptides in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-adrenal axis and clinical measures.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Inhibition of Adrenocorticotropin Secretion by Somatostatin in Pituitary Cells in Culture*

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

CSF corticotropin-releasing hormone in depressed patients and normal control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

CSF Somatostatin in Affective Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Effects of carbamazepine on cerebrospinal fluid somatostatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Cerebrospinal fluid somatostatin and psychiatric illness

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Cerebrospinal fluid somatostatin concentrations in schizophrenia and schizoaffective disorder: the effects of antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Elevation of CSF somatostatin concentrations in mania

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Immunoreactive corticotropin-releasing factor concentrations in cerebrospinal fluid from patients with hypothalamic-pituitary-adrenal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Monoamine metabolites in CSF and suicidal behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

Measuring receptor occupancy with PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900073-6

7 January 2021

10.1016/S0924-977X(01)00073-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11313159%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference